Brokerages Set Caribou Biosciences, Inc. (NASDAQ:CRBU) Price Target at $9.33

Caribou Biosciences, Inc. (NASDAQ:CRBU) has earned a consensus rating of “Buy” from the five brokerages that are presently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $9.33.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th.

Caribou Biosciences Price Performance

Shares of NASDAQ:CRBU opened at $0.82 on Monday. The company has a market capitalization of $76.16 million, a P/E ratio of -0.50 and a beta of 2.36. Caribou Biosciences has a 1 year low of $0.66 and a 1 year high of $3.84. The business’s 50 day simple moving average is $0.87 and its 200 day simple moving average is $1.44.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.43). The firm had revenue of $2.35 million for the quarter, compared to the consensus estimate of $1.48 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. On average, sell-side analysts anticipate that Caribou Biosciences will post -1.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CRBU. Centric Wealth Management bought a new position in shares of Caribou Biosciences in the 4th quarter valued at $27,000. Cerity Partners LLC lifted its stake in shares of Caribou Biosciences by 163.6% in the 1st quarter. Cerity Partners LLC now owns 40,722 shares of the company’s stock valued at $37,000 after acquiring an additional 25,271 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Caribou Biosciences by 859.0% in the 4th quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock valued at $38,000 after acquiring an additional 21,416 shares during the last quarter. MetLife Investment Management LLC lifted its stake in shares of Caribou Biosciences by 60.0% in the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock valued at $39,000 after acquiring an additional 9,148 shares during the last quarter. Finally, Diametric Capital LP bought a new position in Caribou Biosciences during the 4th quarter worth $42,000. 77.51% of the stock is currently owned by institutional investors.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.